Chicago Capital LLC boosted its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 126.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,080 shares of the medical research company's stock after purchasing an additional 5,629 shares during the period. Chicago Capital LLC's holdings in Exact Sciences were worth $566,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of EXAS. Huntington National Bank increased its stake in shares of Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after buying an additional 352 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in shares of Exact Sciences in the third quarter valued at about $34,000. Capital Performance Advisors LLP acquired a new stake in Exact Sciences during the third quarter worth approximately $35,000. Modus Advisors LLC acquired a new stake in Exact Sciences during the fourth quarter worth approximately $43,000. Finally, Vestor Capital LLC acquired a new stake in Exact Sciences during the third quarter worth approximately $46,000. Institutional investors and hedge funds own 88.82% of the company's stock.
Exact Sciences Stock Performance
Shares of EXAS traded down $1.50 during trading hours on Thursday, reaching $54.28. 1,227,907 shares of the company traded hands, compared to its average volume of 2,242,256. The stock has a market capitalization of $10.05 billion, a P/E ratio of -46.39 and a beta of 1.24. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The business has a fifty day moving average price of $57.63 and a 200-day moving average price of $59.97.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm had revenue of $708.66 million for the quarter, compared to analysts' expectations of $716.80 million. Exact Sciences's quarterly revenue was up 12.8% on a year-over-year basis. Equities analysts anticipate that Exact Sciences Co. will post -1.1 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms recently commented on EXAS. Canaccord Genuity Group decreased their target price on Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Evercore ISI decreased their target price on Exact Sciences from $80.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group cut their price target on Exact Sciences from $75.00 to $65.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Barclays started coverage on Exact Sciences in a report on Thursday, January 23rd. They issued an "overweight" rating and a $70.00 target price on the stock. Finally, Bank of America dropped their target price on Exact Sciences from $75.00 to $72.00 and set a "buy" rating on the stock in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $72.76.
View Our Latest Analysis on EXAS
Insider Transactions at Exact Sciences
In other news, CEO Kevin T. Conroy purchased 19,500 shares of the business's stock in a transaction dated Wednesday, November 13th. The stock was acquired at an average price of $51.35 per share, for a total transaction of $1,001,325.00. Following the acquisition, the chief executive officer now directly owns 1,074,191 shares of the company's stock, valued at approximately $55,159,707.85. This represents a 1.85 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.36% of the company's stock.
About Exact Sciences
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
See Also
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
